Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-ASC-DFU for Deep Second-degree Burn Injury
NCT02619851Phase 2Completed
- Sponsor
- Anterogen Co., Ltd.
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allo-asc in burn injury (2 arms), sponsored by Anterogen Co., Ltd. Primary endpoint: Time of re-epithelialization at 12 weeks. Started Dec 2015; status: completed.
02
Drugs
allo-asc
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT02619851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619851.